Login
$RMD
$239.10 +$0.91 (0.38%) After hours

$RMD 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition; Other Events

Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basis

01 Sep 2026 8-K: Other Events

On August 31, 2026, ResMed Inc. (the “Company”) entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Citibank, N.A. (“Citibank”) to repurchase $450.0 million of the Company’s shares of common stock, par value...

17 Aug 2026 8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation +1 more

Nominating and Governance Chair Carol Burt to become Lead Director.

06 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis

07 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Sharpens Resmed’s focus on high-growth sleep and connected care markets

30 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, ...

30 Apr 2026 8-K: Results of Operations and Financial Condition; Other Events

Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis

29 Jan 2026 8-K: Results of Operations and Financial Condition; Other Events

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis

20 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

30 Oct 2025 8-K: Results of Operations and Financial Condition; Other Events

Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis

18 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations

01 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

31 Jul 2025 8-K: Results of Operations and Financial Condition; Other Events

Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%

23 Apr 2025 8-K: Results of Operations and Financial Condition; Other Events

Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%

30 Jan 2025 8-K: Results of Operations and Financial Condition; Other Events

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%

21 Nov 2024 8-K: Submission of Matters to a Vote of Security Holders

On November 20, 2024, at our annual meeting of stockholders, our stockholders (1) elected the eleven nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public ac...

24 Oct 2024 8-K: Results of Operations and Financial Condition; Other Events

Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%

16 Aug 2024 8-K: Departure/Election of Directors or Officers; Compensation

ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board

01 Aug 2024 8-K: Results of Operations and Financial Condition; Other Events

Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%

25 Apr 2024 8-K: Results of Operations and Financial Condition; Other Events

Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support